Abstract
Study: The aim of this single-center, a retrospective study was to evaluate early and long-term adverse events in advanced heart failure patients with cardiogenic shock who underwent ventricular assist device (VAD) implantation. We hypothesize that outcomes in patients implanted with LVAD with INTERMACS 1 have increased the risk of perioperative bleeding and infection. Methods: We evaluated outcomes in 191 patients with a HeartMate II LVAD implanted between May 2008 and June 2014 at the University of Rochester Medical Center, enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Registry. Patients were divided into two groups: A) INTERMACS level 1 (cardiogenic shock) or B) INTERMACS level>1 (noncardiogenic shock). Preoperative characteristics, as well as post-surgical bleeding, infection and all-cause mortality, were assessed. The original LVAD database has received exempt status from the RSRB (RSRB00043111). Results: From 191 patients, there were 59 patients with INTERMACS level 1, and 132 with INTERMACS level greater than 1. Patients with INTERMACS level 1 at LVAD implantation were younger. Following LVAD implantation, INTERMACS level 1 patients had a trend towards bleeding and infection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
